Recovery from deadly influenza infection may hinge on helping the lungs heal in addition to stopping the virus, according to ...

Researchers have found in the phase II SOLSTICE trial that the investigational combination of tobevibart plus elebsiran ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Reports of halted research and clinical trials contradict Health Secretary Robert F. Kennedy Jr.’s statement that the Trump administration hasn’t cut science and research. One recent research letter ...

The Epstein-Barr Virus (EBV) market is rapidly expanding, driven by increased recognition of its association with various diseases, including cancers and autoimmune disorders. EBV, affecting over 90% ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

This retrospective cohort study used data from the Veterans Health Administration to assess the association between chronic untreated HCV and incident PDAC and whether different HCV genotypes affect ...

Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387. NanoViricides, Inc. (NYSE American: NNVC) filed its Form 10-Q for the quarter ended Sept. 30, 2025, and detailed progress ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...

The Hepatitis B and C Therapeutics Market has entered a renewed growth cycle in 2024, led by innovative antiviral regimens, ...

The ASX healthcare sector ended the week ending November 21, 2025 down, following a sharp sell-off as on Wall Street and ...